

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,512
Filing Date	May 23, 2006
First Named Inventor	Ichikawa, Yoshitaka
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	8031-013-US

Sheet	1	of	4
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

¹ EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP § 809. Draw line through citation if not in conformance are not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP § 01.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the index of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. ⁷ Applicant is to place a check mark here if English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	2	of	4
-------	---	----	---

Application Number	10/580,512
Filing Date	May 23, 2006
First Named Inventor	Ichikawa, Yoshitaka
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	8031-013-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ALTMAN, R. D., et al., "Practice Guidelines in the Management of Osteoarthritis," Osteoarthritis and Cartilage, (1998), 6(Supp.A):22-24.	
		BOHNE, W., "Glukosamine In Der Konservativen Arthrosebehandlung," Med. Welt. Nr., (1969), 30:1668-1671.	
		CHU, S. C., et al., "Analysis of the Cytokine-Stimulated Human Inducible Nitric Oxide Synthase (iNOS) Gene...", Biochem. Biophys. Res. Commun., (1998), 248:871-878.	
		CHOU, T., et al., "Glycosylation of the c-Myc transactivation domain," Proc. Natl. Acad. Sci. USA, (1995), 92:4417-4421.	
		DE VRIES, B. J., et al., "Quantitation of glycosaminoglycan metabolism in anatomically intact articular cartilage of the mouse...", Rheumatol. Int. (1986) 6:273-281.	
		DIEPPE, P., "Molecular Markers for Joint and Skeletal Diseases: Notes from the General Discussion," Acta. Orthop. Scand., (1995), 66(Supp.266):211-212.	
		FINGL, E. et al., "The Pharmacological Basis of Therapeutics," (1975), Chapter 1:1-46.	
		GABRIEL, S. E., et al., "Direct Medical Costs Unique to People with Arthritis," J. Rheumatol., (1997), 24:719-725.	
		GENG, Y., et al., "Tyrosine Kinases Are Involved With the Expression of Inducible Nitric Oxide Synthase in Human Articular...", J. Cell. Physiol., (1995), 163:545-554.	
		HALTIWANGER, R. S., et al., "O-Glycosylation of Nuclear and Cytoplasmic Proteins: Regulation Analogous...", Biochem. Biophys. Res. Commun., (1997), 231:237-242.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit if the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,512
Filing Date	May 23, 2006
First Named Inventor	Ichikawa, Yoshitaka
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	8031-013-US

Sheet **3** of **4****NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HEVEL, J. M., et al., "Nitric-Oxide Synthase Assays," Methods Enzymol., (1994), 233:250-258.	
		HOCHBERG, M. C., et al., "Guidelines for the Medical Management of Osteoarthritis," Arthritis & Rheumatism, (1995), 38(11):1535-1546.	
		INEROT, S., et al., "Articular-Cartilage Proteoglycans in Aging and Osteoarthritis," Biochem. J., (1978), 169:143-156.	
		KORNFELD, S., et al., "The Feedback Control of Sugar Nucleotide Biosynthesis in Liver," Proc. Natl. Acad. Sci. USA, (1964), 52:371-379.	
		KOLM-LITTY, J., et al., "High Glucose-induced Transforming Growth FactorB1 Production is Mediated by the Hexosamine Pathway....," J. Clin. Invest., (1998), 101(1):160-169.	
		KARIN, M., "The Beginning of the End: Ikb Kinase (IKK) and NF-kB Activation," J. Biol. Chem., (1999), 274(39):27339-27342.	
		LAWRENCE, R. C., et al., "Estimates of the Prevalence of Arthritis and Selected Musculoskeletal Disorders....," Arthritis & Rheumatism, (1998), 41(5):778-799.	
		LOZADA, C. J., et al., "Chondroprotection in Osteoarthritis," Bull. Rheum. Dis., (1997), 46(7):5-7.	
		MEVORACH, D., et al., "Osteoarthritis and Chondroprotection," Isr. J. Med. Sci., (1994), 30:928-931.	
		MARCH, L. M., et al., "Economics of Osteoarthritis: A Global Perspective," Bailliere's Clinical Rheumatology, (1997), 11(4):817-834.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which it is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if known

Sheet	4	of	4	Application Number	10/580,512
				Filing Date	May 23, 2006
				First Named Inventor	Ichikawa, Yoshitaka
				Art Unit	1614
				Examiner Name	TBA
				Attorney Docket Number	8031-013-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NEWTON, R., et al., "Superinduction of COX-2 mRNA By Cycloheximide and Interleukin-1B Involves Increased Transcription and Correlates....," FEBS Letters, (1997), 418:135-138.	
		PARIKH, A. A., et al., "IL-6 Production in Human Intestinal Epithelial Cells Following Stimulation with IL-1 B Is Associated....," J. Clin. Research, (1997), 69:139-144.	
		SANDY, J. D., et al., "Chondrocyte-Mediated Catabolism of Aggrecan: Aggrecanase-Dependent Cleavage Induced by Interleukin-1....," Biochem. J. (1998), 335:59-66.	
		SANDY, J. D., et al., "Chondrocyte-Mediated Catabolism of Aggrecan: Evidence for a Glycosylphosphatidylinositol-Linked....," Arch. Biochem. Biophys. (1999), 367(2):258-264.	
		SETNIKAR, I., et al., "Antireactive properties of Glucosamine Sulfate," Arzneim-Forsch./Drug Res...., (1991), 41(1):157-161.	
		SCHARSTUHL, A., et al., "Loss of Transforming Growth Factor Counteraction on Interleukin 1 Mediated Effects in Cartilage of Old Mice," Ann. Rheum. Dis., (2002), 61:1095-1098.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.